ENTA stock sentiment todayEnanta Pharmaceuticals Inc
Sentiment verdict
Gossip first, financials second — COLD at 75% confidence.
Last updated · cached analysis, refreshes periodically
ENTA
Enanta Pharmaceuticals IncA cash-burning biotech struggling to pivot beyond its declining HCV royalty stream while facing setbacks in its respiratory pipeline.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for ENTA. Not financial advice.
Price · last 12 months
Gossip
Market sentiment is weighed down by the lack of near-term catalysts and disappointment over the RSV clinical trials. Investors are skeptical about the company's ability to replace the AbbVie royalty revenue as hepatitis C treatments reach market saturation.
- ·Pipeline setbacks in RSV (Respiratory Syncytial Virus) programs
- ·Declining royalties from Mavyret (AbbVie partnership)
- ·Lack of M&A interest compared to peers with late-stage assets
Financial
Enanta is characterized by significant net losses and a shrinking revenue base. While they hold a decent cash position of approximately $280M, the high R&D burn rate limits their runway without further dilution or a major clinical win.
- ·Negative EPS with consistent quarterly misses
- ·Falling royalty revenue from the AbbVie partnership
- ·High R&D-to-revenue ratio causing rapid cash depletion
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·No open-market insider trades in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Clinical trial failure risk for EDP-323 and other early-stage respiratory candidates
- ·Further decline in the global Hepatitis C market impacting cash flow
- ·Need for dilutive financing if pipeline progress stalls
Peer temperature
How direct competitors stack up against ENTA right now.
- HOTGILDGilead Sciences, Inc.
HOTTER — offers a stable dividend and a massive oncology portfolio that offsets the same HCV headwinds Enanta is facing.
See full analysis → - HOTVRTXVertex Pharmaceuticals
HOTTER — boasts a dominant monopoly in Cystic Fibrosis with vastly superior margins and a successful expansion into pain management.
See full analysis → - NEUTRALALNYAlnylam Pharmaceuticals
WARMER — despite high spend, they have a proven RNAi platform and commercialized products with significantly higher growth velocity than ENTA.
See full analysis →
- ENTA+2.9%
- GILD+11.6%
- VRTX+15.7%
- ALNY+9.2%
AI-generated analysis for informational purposes only. Not financial advice.